NFL Biosciences SA (EPA:ALNFL)

France flag France · Delayed Price · Currency is EUR
1.708
+0.018 (1.07%)
May 2, 2025, 5:00 PM CET
-7.17%
Market Cap 16.79M
Revenue (ttm) 46.00
Net Income (ttm) -2.08M
Shares Out 9.83M
EPS (ttm) -0.21
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 32,669
Average Volume 32,163
Open 1.670
Previous Close 1.690
Day's Range 1.600 - 1.754
52-Week Range 1.300 - 3.280
Beta 1.44
RSI 60.04
Earnings Date Mar 28, 2025

About NFL Biosciences

NFL Biosciences SA, a biotechnology company, engages in the development of natural addiction withdrawal solutions for smokers. Its pipeline includes NFL-101, a drug candidate for smoking cessation, currently under Phase 2b clinical trials; NFL-201, a drug candidate for cannabis addiction currently in preclinical stage; and NFL-301, a drug candidate for reducing alcohol consumption, currently under in preclinical stage. The company was incorporated in 2006 and is based in Castelnau-le-Lez, France. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 5
Stock Exchange Euronext Paris
Ticker Symbol ALNFL
Full Company Profile

Financial Performance

In 2024, NFL Biosciences's revenue was 46, a decrease of -99.98% compared to the previous year's 200,011. Losses were -2.08 million, -44.44% less than in 2023.

Financial Statements

News

There is no news available yet.